(Q41521818)

2 October 2017

title

Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline (English)

1 reference

2 October 2017

1 reference

1 reference

Andreas H Diacon

1

1 reference

2 October 2017

Rodney Dawson

2

1 reference

2 October 2017

Florian von Groote-Bidlingmaier

3

1 reference

2 October 2017

Gregory Symons

4

1 reference

2 October 2017

Amour Venter

5

1 reference

2 October 2017

Peter R Donald

6

1 reference

2 October 2017

Christo van Niekerk

7

1 reference

2 October 2017

Daniel Everitt

8

1 reference

2 October 2017

Jane Hutchings

9

1 reference

2 October 2017

Divan A Burger

10

1 reference

2 October 2017

Robert Schall

11

1 reference

2 October 2017

Carl M Mendel

12

1 reference

2 October 2017

language of work or name

English

0 references

publication date

1 April 2015

1 reference

American Journal of Respiratory and Critical Care Medicine

2 October 2017

published in

1 reference

2 October 2017

volume

191

1 reference

2 October 2017

issue

8

1 reference

2 October 2017

page(s)

943-953

1 reference

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

The early bactericidal activity of anti-tuberculosis drugs: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Phase II dose-ranging trial of the early bactericidal activity of PA-824

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Pyrazinamide pharmacokinetics and efficacy in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Clofazimine: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201410-1801OC

10.1164/RCCM.201410-1801OC

21 January 2018

Identifiers

DOI

1 reference

2 October 2017

1 reference